With enhancements and continued patient focus, expedited regulatory pathways still delivering, EMA official says

6 October 2023
ema-2022-european-union-2022-large2

Leading regulatory bodies around the world have various pathways in place to speed up the approval process for promising medicines that offer a solution to unmet medical needs.

The European Medicines Agency (EMA) is no exception, and its schemes are subject to regular review to see how well each is performing, according to Michael Berntgen, head of the Scientific Evidence Generation Department.

Dr Berntgen explained the objectives of these schemes during an interview with The Pharma Letter at last week’s European Health Forum Gastein meeting in Austria.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical